C

Cencora

Distributes medicines and supports patient care

Spécialiste de Remboursement Bilingue/Reimbursement Specialist

Full-TimePosted on 10/19/2026
CA$43.4k - CA$68k
Junior
Prince Edward Island, Canada+11 moreMore locations: Alberta, Canada | Newfoundland and Labrador, Canada | British Columbia, Canada | New Brunswick, Canada | Saskatchewan, Canada | Ontario, Canada | Yukon, Canada | Northwest Territories, Canada | Nova Scotia, Canada | Manitoba, Canada | Québec City, QC, Canada
Remote
Medical, Clinical & VeterinaryClinical Support & Patient Administration

About the job

Requirements
  • A minimum of one year of experience in the pharmaceutical, insurance, or healthcare-related industries is required.
  • Previous experience in reimbursement and knowledge of public, private, and federal reimbursement are required.
  • A minimum of one year of experience in a customer service setting is required.
  • Strong proficiency in Microsoft applications, including Outlook, Word, and Excel, is required.
  • The candidate must be able to organize time, set priorities, and multitask to meet competing work deadlines.
  • The candidate must have strong communication and interpersonal skills, including the ability to communicate with patients in a healthcare setting about extremely sensitive topics.
  • The candidate must be able to work independently and in a team environment.
  • Attention to detail is required.
  • Bilingualism in French and English is required.
  • Advanced knowledge of the pharmaceutical or insurance industry is required.
  • Strong business and financial acumen are required.
  • Strong analytical and mathematical skills are required.
  • The ability to communicate effectively both orally and in writing is required.
  • Effective interpersonal and leadership skills are required.
  • Effective organizational skills and attention to detail are required.
  • The ability to consistently meet deadlines is required.
  • Excellent problem-solving skills and the ability to resolve issues effectively and efficiently are required.
  • Post-secondary education or equivalent in a related discipline is required.
Responsibilities
  • Communicate daily and on an ongoing basis with the Program Manager or Associate Program Manager about new and existing projects.
  • Demonstrate in-depth knowledge of rare disease program offerings, including disease and product pathophysiology, therapeutic areas, disease processes, mechanisms of action, and application of rare disease standard operating procedures.
  • Exhibit in-depth knowledge of public, private, and federal funding mechanisms and rare disease funding bodies in the United States and Canada.
  • Coordinate cases with physicians and healthcare professionals to prepare submissions that meet specifications and criteria set by public and private payers.
  • Coordinate and manage all aspects required to obtain prescription drug coverage for patients.
  • Coordinate cases with insurance companies, physicians’ offices, and healthcare professionals to maximize reimbursement solutions.
  • Navigate the lobbying process to obtain prescription drug coverage and reimbursement for costly medications.
  • Coordinate documents, submissions, and related paperwork with insurance companies and public and federal funding programs.
  • Implement financial means tests as required to maximize patient prescription drug coverage.
  • Coordinate pharmacy processes after funding has been obtained.
  • Report all adverse events to the assigned units or departments.
  • Perform other duties and tasks as assigned.
Desired Qualifications
  • Experience in the healthcare, pharmaceutical, or insurance industry is an asset.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Financial News
Oct 21st, 2026
Cencora to buy American Oncology Network in $2.4bn deal

Cencora agrees to buy American Oncology Network for $2.4bn enterprise value, but a stockholder rollover means it may land only 75% of the company.

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.